TOGETHER LONGER

Superior overall survival with Vyxeos Liposomal over 5 years vs. daunorubicin and cytarabine (DA) therapy in high-risk* acute myeloid leukaemia (AML)1

Vyxeos Liposomal is the first dual-drug advanced liposomal formulation of DA2

Jumbotron image

NOW AVAILABLE: 5-YEAR PHASE 3 DATA FOR VYXEOS LIPOSOMAL IN HIGH-RISK* AML

Superior overall survival vs. DA therapy1

Discover more

Similar safety profile with prolonged myelosuppression vs. DA therapy1,3

Discover more

Simplified infusion schedule reduces the number of administration days vs. DA therapy3-5

Discover more

The American Society of Hematology (ASH) Guidelines: A Summary by Dr Priyanka Mehta

A brief summary from Dr Priyanka Mehta of the latest American Society of Hematology (ASH) recommendations for the treatment of older patients with AML.

UK-VYX-2100030 | March 2021

5-Year Data for Vyxeos Liposomal: Perspectives From the United Kingdom (UK)

Watch as physicians from leading UK haematology centres share their thoughts on the 5-year results of Vyxeos Liposomal in Study 301, presented at the European Hematology Association (EHA) Virtual Congress 2020.1

UK-VYX-2000171 | March 2021

ADVERSE EVENTS REPORTING

Adverse events should be reported. Reporting forms and information for the UK can be found at https://yellowcard.mhra.gov.uk/

For Ireland, reporting forms and information can be found at: www.hpra.ie

Adverse events should also be reported to Jazz Pharmaceuticals at AEreporting@jazzpharma.com

IE-VYX-2100004 l September 2021